Recent advances in our understanding of the environmental, epidemiological, immunological, and clinical dimensions of coccidioidomycosis

C Nguyen, BM Barker, S Hoover, DE Nix… - Clinical microbiology …, 2013 - Am Soc Microbiol
Coccidioidomycosis is the endemic mycosis caused by the fungal pathogens Coccidioides
immitis and C. posadasii. This review is a summary of the recent advances that have been …

Utility of voriconazole therapeutic drug monitoring: a meta-analysis

ML Luong, M Al-Dabbagh, AH Groll… - Journal of …, 2016 - academic.oup.com
Background Voriconazole therapeutic drug monitoring (TDM) is increasingly used in clinical
practice. However, the utility of voriconazole TDM to guide therapy remains uncertain and …

Therapeutic drug monitoring of systemic antifungal agents: a pragmatic approach for adult and pediatric patients

J John, A Loo, S Mazur, TJ Walsh - Expert opinion on drug …, 2019 - Taylor & Francis
Introduction: Therapeutic drug monitoring (TDM) has been shown to optimize the
management of invasive fungal infections (IFIs), particularly for select antifungal agents with …

UPLC-MS/MS method for the simultaneous determination of imatinib, voriconazole and their metabolites concentrations in rat plasma

R Xu, Q Lin, X Qiu, J Chen, Y Shao, G Hu… - Journal of Pharmaceutical …, 2019 - Elsevier
In the present study, a simple ultra-performance liquid chromatography tandem mass
spectrometry (UPLC-MS/MS) method used to measure the plasma concentrations of …

Voriconazole pharmacokinetics and exposure–response relationships: assessing the links between exposure, efficacy and toxicity

MJ Dolton, AJ McLachlan - International journal of antimicrobial agents, 2014 - Elsevier
The triazole antifungal voriconazole (VCZ) exhibits broad-spectrum antifungal activity and is
the first-line treatment for invasive aspergillosis. Highly variable, non-linear …

Achieving target voriconazole concentrations more accurately in children and adolescents

M Neely, A Margol, X Fu, M van Guilder… - Antimicrobial agents …, 2015 - Am Soc Microbiol
Despite the documented benefit of voriconazole therapeutic drug monitoring, nonlinear
pharmacokinetics make the timing of steady-state trough sampling and appropriate dose …

Therapeutic drug monitoring of antifungal drugs: another tool to improve patient outcome?

A Vena, P Muñoz, M Mateos, J Guinea, A Galar… - Infectious Diseases and …, 2020 - Springer
Introduction This study aimed to examine the relationship among adequate dose, serum
concentration and clinical outcome in a non-selected group of hospitalized patients …

Recent advances in therapeutic drug monitoring of voriconazole, mycophenolic acid, and vancomycin: a literature review of pediatric studies

M Resztak, J Sobiak, A Czyrski - Pharmaceutics, 2021 - mdpi.com
The review includes studies dated 2011–2021 presenting the newest information on
voriconazole (VCZ), mycophenolic acid (MPA), and vancomycin (VAN) therapeutic drug …

Effect of therapeutic drug monitoring and cytochrome P450 2C19 genoty** on clinical outcomes of voriconazole: a systematic review

J Lee, P Ng, B Hamandi, S Husain… - Annals of …, 2021 - journals.sagepub.com
Objectives To examine current knowledge on the clinical utility of therapeutic drug
monitoring (TDM) in voriconazole therapy, the impact of CYP2C19 genotype on …

Challenges in the treatment of invasive aspergillosis in immunocompromised children

AJ Hsu, PD Tamma, BT Fisher - Antimicrobial agents and …, 2022 - Am Soc Microbiol
Invasive aspergillosis (IA) is associated with significant morbidity and mortality. Voriconazole
remains the drug of choice for the treatment of IA in children; however, the complex kinetics …